ZYUS Life Sciences secures U.S. patent for novel non-opioid pain management drug formulation

ZYUS Life Sciences Corporation announced the issuance of a U.S. patent for a novel cannabichromene (CBC) formulation aimed at managing chronic and neuropathic pain without opioids. This patent strengthens their intellectual property portfolio and supports ongoing clinical research for their second drug candidate targeting conditions like diabetic and cancer-related neuropathies. The patent complements their existing lead drug, Trichomylin® softgel capsules, and paves the way for potential clinical trials and regulatory approval in the U.S. This development highlights ZYUS' commitment to innovative, non-opioid pain therapies addressing significant unmet medical needs.